secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001628280-24-020447
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR
--------------------------------------------------------------------------------

- ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.
- Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.
- Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.
- LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.
- Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/adc-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer